WHO and EMA statements on potential safety issue affecting women living with HIV using dolutegravir

This website uses cookies to improve your experience while you are browsing and to help us understand how you use this Website.
By clicking “Accept All” you agree to receive ALL cookies on our Website.
You can reject the cookies that are not “technical and necessary” customizing your choices by clicking on “Cookie settings”.
If you close this banner by clicking the "X" button, default settings will remain in place and you will continue to browse the Website only with “technical and necessary cookies”.
You can review and change your choices at any time by accessing the Management consent panel.
If you would like to learn more about how cookies work on the Website, read our Privacy Policy and Cookies Policy.